Table 1.
PEGylated Drugs Approved by FDA
| Brand Name | Company | Year Approved | PEGylated Molecule | Indication(s) | PEG# |
|---|---|---|---|---|---|
| Adagen | Enzon | 1990 | enzyme | Severe combined immunodeficiency disease | multiple × 5 kDa |
| Oncaspar | Enzon | 1994 | enzyme | Acute lymphoblastic leukemia | 69-82 × 5 kDa |
| Doxil | Ortho/Schering-Plough | 1995 | liposome | Cancer | |
| PEGasys | Roche | 2001 | protein | Hepatitis B&C | 40 kDa, branched |
| PegIntron | Schering-Plough | 2001 | protein | Hepatitis C | 12 kDa |
| Neulasta | Amgen | 2002 | protein | Chemotherapy induced neutropenia | 20 kDa |
| Somavert | Pfizer | 2003 | protein | Acromegaly | 4-6 × 5 kDa |
| Macugen | Pfizer | 2004 | aptamer | Neovascular age-realted macular degeneration | 2 × 20 kDa |
| Mircera | Roche | 2007 | protein | Anemia associated with chronic kidney disease | 30 kDa |
| Cimzia | UCB | 2008 | FAB’ fragment | Crohn's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | 40 kDa, branched |
| Krystexxa | Savient | 2010 | enzyme | Gout | 9-11 × 10 kDa |
| Sylatron | Merck | 2011 | protein | Melanoma* | 1 × 12 kDa |
| Omontys | Affymax/Takeda** | 2012 | peptide | Anemia associated with chronic kidney disease | 1 × 40 kDa, branched |
| Movantik | AstraZeneca/Nektar | 2014 | small molecule, oral | Non-cancer opiod-induced constipation | <1 kDa |
#
PEG is linear unless otherwise noted
*
with nodal involvement after surgical resection
**
recalled for hypersensitivity